High Incidence of Bloodstream Infection Due to Gram-negative Bacilli in Patients With Pulmonary Hypertension Receiving Intravenous Treprostinil;Alta incidencia de bacteriemia por bacilos gramnegativos en pacientes con hipertensión pulmonar tratados con treprostinil por vía intravenosa

Archivos de Bronconeumologia

Volumn 48, Issue 12, 2012, Pages 443-447

  López Medrano, Francisco ^a   Fernández Ruiz, Mario ^a   Ruiz Cano, María José ^a   Barrios, Elvira ^a   Vicente Hernández, María ^a   Aguado, José María ^a   Escribano, Pilar ^a  

^a Universidad Complutense ^*  (Spain)

Author keywords

Bacteremia; Epoprostenol; Prostanoid; Pulmonary arterial hypertension; Treprostinil

Indexed keywords

PROSTACYCLIN; TREPROSTINIL;

ARTICLE; BACTEREMIA; BLOODSTREAM INFECTION; CONTINUOUS INFUSION; ENTEROBACTER CLOACAE; FOLLOW UP; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE SEPSIS; GRAM POSITIVE COCCI; HUMAN; INCIDENCE; INFECTION RISK; MAJOR CLINICAL STUDY; NONHUMAN; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; RISK ASSESSMENT; STAPHYLOCOCCUS AUREUS; TREATMENT DURATION;

EID: 84870301899     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/j.arbr.2012.09.008     Document Type: Article

References (13)

1. Galiè N., Palazzini M., Leci E., Manes A. Current therapeutic approaches to pulmonary arterial hypertension. Rev Esp Cardiol 2010, 63:708-724.
2. Escribano Subías P., Jiménez López-Guarch C., Flox Camacho A. Tratamiento farmacológico con prostaciclina y sus análogos. Tratado de hipertensión pulmonar 2009, 355-376. Ars Medica, Barcelona. A. Sueiro Bendito, J. Gaudó Navarro (Eds.).
3. Agencia Española de Medicamentos y Productos Sanitarios (AEMSP). Ficha técnica de epoprostenol (Flolan) [consultado 14 Ene 2012]. Disponible en: https://sinaem4.agemed.es/consaem/especialidad.do%3Fmetodo=verFichaWordPdf%26codigo=57757%26formato=pdf%26formulario=FICHAS.
4. Prospecto de embalaje de treprostinil (Remodulin) 2006, United Therapeutics Corporation, Research Triangle Park, NC.
5. Laliberte K., Arneson C., Jeffs R., Hunt T., Wade M. Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers. J Cardiovasc Pharmacol 2004, 44:209-214.
6. Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension-seven sites, United States, 2003-2006. MMWR Morb Mortal Wkly Rep 2007, 56:170-172. Centers for Disease Control Prevention (CDC).
7. Kallen A.J., Lederman E., Balaji A., Trevino I., Petersen E.E., Shoulson R., et al. Bloodstream infections in patients given treatment with intravenous prostanoids. Infect Control Hosp Epidemiol 2008, 29:342-349.
8. Rich J.D., Glassner C., Wade M., Coslet S., Arneson C., Doran A., et al. The effect of diluent pH on bloodstream infection rates in patients receiving IV treprostinil for pulmonary arterial hypertension. Chest 2012, 141:36-42.
9. Zaccardelli D., Phares K., Jeffs R., Doran A., Wade M. Stability and antimicrobial effectiveness of treprostinil sodium in sterile diluent for Flolan. Int J Clin Pract 2010, 64:885-891.
10. Pinilla M.I., Cobos-Trigueros N., Soriano A., Martínez J.A., Zboromyrska Y., Almela M., et al. Bacteriemias por Burkholderia cepacia: análisis prospectivo de 33 episodios. Rev Esp Quimioter 2011, 24:209-212.
11. Looney W.J., Narita M., Mühlemann K. Stenotrophomonas maltophilia: an emerging opportunist human pathogen. Lancet Infect Dis 2009, 9:312-323.
12. Falagas M.E., Valkimadi P.E., Huang Y.T., Matthaiou D.K., Hsueh P.R. Therapeutic options for Stenotrophomonas maltophilia infections beyond co-trimoxazole: a systematic review. J Antimicrob Chemother 2008, 62:889-894.
13. Marcos M., Soriano A., Iñurrieta A., Martínez J.A., Romero A., Cobos N., et al. Changing epidemiology of central venous catheter-related bloodstream infections: increasing prevalence of Gram-negative pathogens. J Antimicrob Chemother 2011, 66:2119-2125.